The Traumakine consortium informed today that the printed version of the article by Bellingan et al., which became available as an online version on December 23rd, 2013, has been now published in the February issue of the The Lancet Respiratory Medicine. This article presents the detailed data of those significant results obtained with FP-1201 treatment of vascular leakage in ARDS patients (acute respiratory distress syndrome) in the phase I/II clinical trial and is attached to this press release for interested readers. The following pan-European phase III clinical study aiming at the European marketing authorization of FP-1201-lyo treatment of ARDS is based on these results and is the key activity of the Traumakine-program.
The Consortium consists of the European Commission as a granting Agency, Faron Pharmaceuticals Ltd as the Coordinator and three other participating Partners of the Traumakine program, University College London Hospital (UCLH), University of Torino and University of Turku.
Referred publication
Bellingan G, Maksimow M, Howell D, Stotz M, Beale R, Beatty M, Walsh T, Binning A, Davidson A, Kuper M, Shah S, Cooper J, Waris M, Yegutkin G, Jalkanen J, Salmi M, Piippo I, Jalkanen M, Montgomery H, Jalkanen S (2014) The effect of intravenous interferon-beta-1a (FP-1201) on lung CD73 expression and on acute respiratory distress syndrome mortality: an open-label study. The Lancet Respiratory Medicine 2014: 2: 98-107.
For more information, please visit:
http://www.faronpharmaceuticals.com
or contact:
Phone: +358-2-469-5151 (Coordinator)
E-mail: info@traumakine.eu